kabutan

PRISM BioLab Co.,LTD(206A) Summary

206A
TSE Growth
PRISM BioLab Co.,LTD
215
JPY
+22
(+11.40%)
Mar 13, 3:30 pm JST
1.34
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
206.1
Mar 13, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.27
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:54 am
243 JPY 1.52 USD
Previous Close Mar 12
193 JPY 1.21 USD
High Mar 13, 9:54 am
243 JPY 1.52 USD
Low Mar 13, 3:12 pm
215 JPY 1.34 USD
Volume
8,814,700
Trading Value
2.06B JPY 0.01B USD
VWAP
233.91 JPY 1.47 USD
Minimum Trading Value
21,500 JPY 134 USD
Market Cap
7.94B JPY 0.05B USD
Number of Trades
5,221
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
438
1-Year High Dec 2, 2025
10,028
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 1,763,800
Feb 27, 2026 0 2,120,000
Feb 20, 2026 0 2,026,900
Feb 13, 2026 100 2,140,700 21407.00
Feb 6, 2026 0 2,249,700
Company Profile
PRISM BioLab Co., LTD engages in the research and development of new drugs using its proprietary drug discovery platform (PepMetics technology).
Sector
Pharmaceuticals
PRISM BioLab is a research and development-oriented venture company focusing on drug discovery utilizing its proprietary PepMetics technology platform. The company is dedicated to creating small molecule drugs targeting intracellular protein-protein interactions (PPIs). By leveraging its unique compound library and synthesis techniques, PRISM BioLab has overcome the challenges associated with traditional approaches, which often resulted in large molecular weight compounds with potential side effects. The company's innovative small molecule compounds have successfully cleared these hurdles, enabling the development of PPI inhibitors. PRISM BioLab has multiple pipelines, including Wnt inhibitors and translation control agents, and pursues both in-house development and collaborative projects with pharmaceutical companies. By pioneering the new drug discovery field of intracellular PPIs, PRISM BioLab aims to create innovative pharmaceuticals for diseases that currently lack effective treatments.